Drugs · 01 Editorial guide
Drugs & pharmaceuticals
Drug compliance follows the product across research, registration, manufacture or import, distribution, use and post-market safety. The marketing authorization holder remains the central quality and safety owner even when work is delegated.
First job Identify product status, licence holder, distribution chain and current regulatory event.
Start here
Key considerations
The first questions are about urgency, governance and preservation — before collection expands or interviews begin.
- What is the product and is it legally a drug, vaccine, traditional Chinese medicine or another regulated category?
- Who holds the China approval and who actually manufactures, imports and distributes it?
- Is the live event registration, quality, supply, promotion, pharmacovigilance, recall or enforcement?
Direct answer
What this page decides
02
A China pharmaceutical file begins with the approved product and its marketing authorization holder, not simply the factory or distributor. Confirm the approval certificate, holder, manufacturer, dosage form, specification, indication, standards and any post-approval commitments. The holder bears lifecycle responsibility for quality, safety and efficacy and must control commissioned manufacturing, distribution traceability, changes, pharmacovigilance and recall even when contractors perform the work. An overseas holder must also maintain the required domestic responsible person. Separate registration or change approval, manufacturing and batch release, distribution licensing and GSP, lawful promotion, adverse-reaction monitoring and a suspected quality defect into distinct workstreams with one controlled chronology.
At a glance
Which fact changes the next route
Use the fact that changes ownership or urgency to decide the next move.
| Question | Why it matters | Next route |
|---|---|---|
| Does the actual product match the approval certificate and current standard? | Formula, process, site, specification, packaging, indication or label differences can require study, approval, filing or reporting before implementation. | Reconcile the marketed product, approval dossier, 2025 Pharmacopoeia and post-approval change record. |
| Who is the holder, manufacturer and China responsible person? | Delegating manufacture or local tasks does not erase the holder's lifecycle responsibility. | Map legal entities, licences, quality agreements, oversight evidence and escalation authority. |
| Can every batch be traced through lawful channels? | Procurement, storage, transport, sale and use controls protect quality and expose unauthorized or counterfeit supply. | Trace the affected batch from release through wholesalers, retailers, platforms and institutions. |
| Is there a quality defect or new safety signal? | Containment, investigation, pharmacovigilance reporting, risk assessment and recall may run on parallel clocks. | Quarantine affected stock, preserve evidence and open the safety/recall decision record. |
Scope
What this page owns — and what it does not
Practical workflow
Action, evidence, legal gate, output
| Action | Documents / evidence | Legal gate | Output |
|---|---|---|---|
| Build the product/approval record | Approval certificate, dossier, specification, indication, label, standards, sites and commitments | Product as made and sold matches current authorization | Approved-state baseline |
| Map lifecycle responsibility | Holder and responsible-person appointments, licences, commissioned-manufacturing and quality agreements | Every regulated function has a lawful entity and accountable quality owner | Responsibility matrix |
| Test operations and traceability | GMP/GSP records, batch release, deviations, change control, distribution, storage, transport and promotion | Continuous compliance from production through use | Gap and affected-batch analysis |
| Control safety and authority response | Complaints, adverse reactions, signals, investigation, risk assessment, recall, inspection and CAPA | Containment, reporting and corrective-action deadlines | Safety and remediation plan |
Documents
What to gather before the next call
These items help clarify the file; they are not a legal requirement list.
| Item | Why needed | Who holds it | Risk if missing |
|---|---|---|---|
| Drug approval certificate and current dossier baseline | Defines the authorized product, holder, manufacturer and conditions | Holder and regulatory affairs | Commercial product diverges from its approval |
| Holder, domestic responsible-person and quality agreements | Allocate execution while preserving holder oversight | Holder, China responsible person and contractors | Delegated work has no effective quality control or escalation |
| Manufacturing, testing and batch-release file | Shows compliance with approved process, GMP and current standards | Manufacturer and holder quality units | A deviation or failing batch reaches market |
| Distribution and traceability record | Identifies lawful sources, storage conditions and affected destinations | Holder, wholesalers, retailers, platforms and institutions | Unauthorized supply or unrecoverable batches |
| Promotion, medical-information and label materials | Tests consistency with approval and advertising/promotion controls | Commercial, medical and compliance teams | Unsupported or off-label promotion |
| Pharmacovigilance, complaint and recall file | Connects signals and defects to investigation, reporting and risk control | Holder safety and quality functions | Delayed containment or incomplete regulator response |
Common failure points
Where files usually break
Treating the manufacturer or distributor as the sole compliance owner while the marketing authorization holder remains passive.
Importing or selling a product, site, dosage form, specification, indication or label that does not match the effective approval.
Implementing post-approval changes before completing the required study, approval, filing or reporting route.
Using a commercial distribution agreement as a substitute for licences, GSP, traceability, storage and transport controls.
Separating complaints, adverse reactions and quality deviations so that a common safety signal is not detected.
Waiting for proof of patient harm before quarantining suspect batches and evaluating reporting or recall duties.
Allowing an overseas holder's China responsible person to become a nominal appointment without information access, resources or escalation authority.
Decision map
Keep the question bounded.
- Fix product and approval statusIdentify active ingredient, dosage form, specification, indication, prescription/OTC status, approval number, holder, sites and current lifecycle stage.
- Map holder and operating partiesSeparate the marketing authorization holder, domestic responsible person for an overseas holder, manufacturer, importer, distributor, online platform and medical institution.
- Control the quality or safety eventConnect registration commitments, current Pharmacopoeia and standards, GMP/GSP, traceability, promotion, pharmacovigilance, change, recall and authority response.
Curated resources
Open the asset that matches this job.
Helpful to prepare
Facts that make the next conversation clearer.
These items are orientation aids, not a legal requirement list.
Counsel hand-off
What to bring when you instruct
This topic route organises the national legal question. It does not decide rights, strategy, liability, approval outcome or procedural result on the facts. Use qualified PRC counsel where fact-specific advice or representation is required.
Local context
Add the city only when it changes implementation.
Add city or province context only when the responsible authority, court, registration practice, permit process or local implementation changes after the national route is identified.
Open city and province guidesCounsel hand-off
Need qualified PRC counsel?
Healthcare counsel can integrate product, facility, clinical, data and reimbursement requirements with the approvals and evidence specific to the matter.
Find counsel by practiceLegal review
Who reviewed this guide
Subject to editorial/legal review. No reviewer is assigned to this route.
Need qualified counsel?
Move carefully. Move with a record.
Use the portal to identify counsel for this practice and related China-side issues.